Convertible Bond Conversion Price Plunges from 1,262 Won to 886 Won, Dilution Risk Soars for Existing Shareholders
Conversion Price Reduction: Poongjeon Pharmacy lowered the conversion price of its 1st series CB from 1,262 won to 886 won, a 29.8% decrease. This contractual adjustment is close to the floor of 70% of the initial conversion price (884 won) triggered by the stock price decline.
Surge in Convertible Shares: Based on the outstanding face value of 4 billion won, the number of convertible shares increased from 3,169,572 to 4,514,672, a 42.4% jump. This represents 51% of total outstanding shares (8,840,635), posing severe dilution risk upon conversion.
Dilution Analysis: With the current stock price at 2,705 won, the new conversion price of 886 won implies a 67.3% discount, offering huge arbitrage gains for bondholders. Full conversion could reduce existing shareholder ownership to as low as 33.4%, an extreme dilution scenario.
Irony of Stock Price Rise: The recent stock price surge has pushed the CB deep in-the-money, ironically increasing the likelihood of conversion and actual dilution for existing shareholders. This creates a structural burden on long-term shareholder value despite short-term price gains.
[AI Summary]While the conversion price adjustment due to market decline is a contractual procedure, the current stock price significantly exceeding the conversion price makes conversion highly probable. This directly translates to a potential ~51% dilution for existing shareholders, and given the unclear use of the initial proceeds, it may weigh negatively on future stock performance.
KOSDAQ Filing Information
Filing: Adjustment of Conversion Price (First Series)